The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I dose-escalation study of TAS-102 in patients (pts) with refractory metastatic colorectal cancer (mCRC).
Manish R. Patel
No relevant relationships to disclose
Johanna C. Bendell
No relevant relationships to disclose
Robert J. Mayer
No relevant relationships to disclose
Fabio M. Benedetti
Employment or Leadership Position - Taiho Pharmaceutical
Lee S. Rosen
Research Funding - Taiho Pharmaceutical